Cytokinetics
CYTK
91 hedge funds and large institutions have $246M invested in Cytokinetics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 18 closing their positions.
161% more call options, than puts
Call options by funds: $3.51M | Put options by funds: $1.35M
62% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 21
3% less capital invested
Capital invested by funds: $254M → $246M (-$8.08M)
4% less funds holding
Funds holding: 95 → 91 (-4)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.65M |
| 3 |
Millennium Management
New York
|
+$3.26M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$900K |
| 5 |
Two Sigma Investments
New York
|
+$822K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Asset Management One
Tokyo,
Japan
| – | -$174K | -18,373 | Closed |
|
|
SIP
102
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$149K | -15,655 | Closed |
|
|
WMSA
103
Weiss Multi-Strategy Advisers
New York
| – | -$125K | -13,122 | Closed |
|
|
BG
104
BlackRock Group
London,
United Kingdom
| – | -$111K | -11,656 | Closed |
|
|
CCMH
105
Cornerstone Capital Management Holdings
New York
| – | -$82K | -8,600 | Closed |
|
|
BJ
106
BlackRock Japan
Tokyo,
Japan
| – | -$7K | -720 | Closed |
|
107
JP Morgan Chase
New York
| – | -$3K | -280 | Closed |
|
|
GC
108
Globeflex Capital
San Diego,
California
| – | -$1K | -83 | Closed |
|
|
GT
109
Glenmede Trust
Philadelphia,
Pennsylvania
| – | +$919 | +88 | New |
|
CYTK Hedge Fund Activity: Q3 2016 in Review
91 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2016, worth a combined $246M — down 3.2% from $254M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CYTK and 14 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 34 added.
The largest buyer was Fidelity Investments, adding an estimated $18.3M. The largest seller was EcoR1 Capital, cutting an estimated $13.5M.
- 91 institutional investors held Cytokinetics (CYTK) as of Q3 2016, down from 95 in Q2 2016.
- Funds reported $246M of Cytokinetics stock for Q3 2016, down 3.2% quarter-over-quarter.
- 14 funds opened new Cytokinetics positions in Q3 2016 and 18 closed out, a net change of -4 holders.
- The largest Cytokinetics buyer in Q3 2016 was Fidelity Investments, an estimated $18.3M added.
- The largest Cytokinetics seller in Q3 2016 was EcoR1 Capital, an estimated $13.5M sold.
Based on aggregated 13F filings for Q3 2016.